Stage I HR-Positive Breast Cancer: Allison's Survivor Story

Patient Info: Allison Tierney, Female | Stage I

Biomarkers: ER-positive; PR-positive; HER2-positive

As of May 2024, Allison had recently completed her cancer treatment journey and reported successful hair preservation with cold capping during Taxol chemotherapy.

The Patient StoryRead more →

At 41, a Tumor Test Supported Chemotherapy for Rare Neuroendocrine Breast Cancer

Patient Info: Anonymized, Female, 40s

Biomarkers: Chromogranin strongly positive; synaptophysin strongly positive; ER score 270; PR score 75; HER2-negative; Ki-67 60%; Oncotype DX Recurrence Score 41

A 41-year-old with a small, node-negative neuroendocrine breast tumor had an Oncotype DX score of 41, supporting chemotherapy despite otherwise early features.

PubMed CentralRead more →

At 40, a Tumor Test Supported Chemotherapy for Rare Neuroendocrine Breast Cancer

Patient Info: Anonymized, Female, 40s

Biomarkers: Chromogranin strongly positive; synaptophysin strongly positive; ER score 300; PR score 240; HER2-negative; Ki-67 35%; Oncotype DX Recurrence Score 38

A 40-year-old with a 1.4 cm, node-negative neuroendocrine breast tumor had a high Oncotype DX score of 38, supporting chemotherapy.

PubMed CentralRead more →

MSI-High Metastatic Hormone-Receptor-Positive Breast Cancer Responding to Pembrolizumab

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; MSI-high; BRCA mutation-negative

Metastatic Site: bone, para-aortic lymph nodes, brain

Pembrolizumab produced marked improvement in metastatic bone and nodal disease. After 1 year it was stopped because of appetite loss; 8 months later she was symptom-free and back at work on endocrine therapy, although asymptomatic brain metastases were documented.

PubMed CentralRead more →

At 45, a Tumor Test Supported Chemotherapy for Rare Neuroendocrine Breast Cancer

Patient Info: Anonymized, Female, 40s

Biomarkers: Chromogranin strongly positive; synaptophysin strongly positive; ER score 300; PR score 270; HER2-negative; Ki-67 40%; Oncotype DX Recurrence Score 32

A 45-year-old with a 2.0 cm, node-negative neuroendocrine breast tumor had a high Oncotype DX score of 32, supporting chemotherapy.

PubMed CentralRead more →

At 53, a Tumor Test Suggested Chemotherapy Could Be Avoided for Rare Breast Cancer

Patient Info: Anonymized, Female, 50s

Biomarkers: Chromogranin strongly positive; synaptophysin strongly positive; ER score 285; PR score 300; HER2-negative; Ki-67 40%; Oncotype DX Recurrence Score 13

A 53-year-old with a 3.0 cm, grade 3 neuroendocrine breast tumor had a low Oncotype DX score of 13, suggesting chemotherapy could be omitted.

PubMed CentralRead more →

Triple-negative breast cancer and ovarian cancer treated with chemotherapy and PARP inhibitor

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Germline pathogenic BRCA2 c.6468_6469del; breast tumor triple-negative

As of April 2024, 6-week follow-up after breast and nodal radiation was unremarkable, erythema had resolved, and no breast, chest wall, respiratory, or axillary abnormality was found; longer-term control was not reported.

PubMed CentralRead more →

Vision problems led to a breast cancer diagnosis (cancer-associated retinopathy)

Patient Info: Anonymized, Female

Biomarkers: Anti-recoverin and anti-alpha-enolase antibodies associated with cancer-associated retinopathy; tumor biomarkers not reported

Six years after her initial visual symptoms, vision remained stable and she remained cancer-free on surveillance.

PubMed CentralRead more →

Sex, dating and intimacy after breast cancer with Charlene Douglas

Patient Info: Anonymized

As of April 2024, this survivorship-focused discussion addressed sex, dating, and intimacy after breast cancer treatment, with practical guidance from Charlene Douglas.

Stage 4 lobular breast cancer: bone therapy switch to denosumab

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Not reported for breast cancer; CRP 21 mg/dL and ESR 27 mm/hr were elevated during orbital inflammation workup

Metastatic Site: bone

As of April 2024, zoledronate-associated ocular inflammation resolved within 2.5 weeks, vision returned to 20/20 after about 3 weeks, and bone-support treatment was changed to denosumab; breast-cancer response was not reported.

PubMed CentralRead more →

Stage I Invasive Lobular Carcinoma: Judith's Survivor Story

Patient Info: Judith, Female | Stage I

Judith’s very early Stage I ILC was found by a supplemental sonogram in June 2021, and she later described herself as cancer-free after working with an ILC-experienced oncology team.

Lobular Breast Cancer AllianceRead more →

Freezing treatment (cryoablation) used to manage slow-growing triple-negative breast cancer

Patient Info: Anonymized, Female | Stage Metastatic/Advanced

Biomarkers: ER-negative; PR-negative; HER2-negative; androgen receptor-positive in original tumor; Ki-67 5% initially and 10% at recurrence

At 29 months after recurrence diagnosis and 20 months after the first cryoablation, no viable breast tumor was seen at treated sites, axillary nodes were unchanged, pain was absent, and she remained active and independent.

PubMed CentralRead more →

Breast Cancer: Allison's Survivor Story

Patient Info: Allison Tierney, Female

Biomarkers: Genetic mutation mentioned; specific mutation not stated in this source

As of April 2024, Allison was a breast cancer survivor and board-certified oncology dietitian using her experience to guide patients on nutrition during treatment and survivorship.

The Patient StoryRead more →

HER2-positive apocrine breast cancer: chemotherapy and Herceptin

Patient Info: Anonymized, Female, 60s

Biomarkers: HER2-positive; AR-positive; ER-negative; PR-negative

Disease-free for 2 years after treatment for HER2-positive apocrine breast cancer, with no reported lymph-node recurrence or distant metastases during surveillance.

PubMed CentralRead more →

Invasive lobular breast cancer with isolated scalp metastasis: excision and endocrine therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Original breast tumor: ER-positive; PR-positive; scalp metastasis: CK7-positive; ER-positive; GCDFP-15 partially positive

Metastatic Site: scalp/skin

As of April 2024, she had no signs of recurrence in the breast or scalp and no distant metastasis after excision of the isolated scalp metastasis while continuing anastrozole.

PubMed CentralRead more →

Stage IV Breast Cancer: Catherine's Survivor Story

Patient Info: Catherine, Female, 40s | Stage IV

Metastatic Site: Brain/cerebellum region

As of April 2024, Catherine said she had been in remission for almost 3 years after a 2019 metastatic recurrence near the cerebellum, while continuing preventive treatment.

YouTube (FR search)Read more →

Metastatic Breast Cancer With Recurrent Severe Hypocalcemia During Treatment - Case 1

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: bone, liver, ovaries

She died about 9 years after her breast-cancer diagnosis after progression of liver metastases.

PubMed CentralRead more →

HER2-Positive Metastatic Breast Cancer With Recurrent Severe Hypocalcemia - Case 2

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: bone, liver

She died about 7 years after her breast-cancer diagnosis after rapid deterioration from liver metastases.

PubMed CentralRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Allison's Patient Story

Patient Info: Allison Tierney, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive; CHEK2 mutation; BRCA1/2 negative

As of March 2024, Allison had completed Taxol and Herceptin treatment, was on tamoxifen planned for 10 years, and had moved to 6-month oncology follow-up. No metastatic disease or recurrence was reported.

YouTube — The Patient StoryRead more →

Stage III Invasive Lobular Carcinoma: Harvey's Patient Story

Patient Info: Harvey, Male, 50s | Stage III

Biomarkers: Genetic testing negative

Harvey was in active treatment for male Stage IIIC grade 3 ILC after right mastectomy and initiation of AC-T chemotherapy, with radiation and endocrine/targeted therapy planned as of March 2024.

Lobular Breast Cancer AllianceRead more →

Stage II Triple-Negative Breast Cancer: Chance's Survivor Story

Patient Info: Chance Osborne, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1 mutation

As of March 2024, Chance Osborne was a young Stage II TNBC survivor with a BRCA1 mutation, sharing her experience with chemotherapy, double mastectomy recovery, and advocacy.

Malignant Phyllodes Tumor Recurs Early Along the Biopsy Tract in a Young Woman

Patient Info: Anonymized, female

Biomarkers: No pathogenic germline mutations identified; MLH1 variant of uncertain significance

Clinical examination, breast MRI, and chest CT showed no evidence of disease at about 3 months after the recurrence surgery and before the 6-month follow-up.

PubMed CentralRead more →

Early-stage breast cancer (DCIS) in a male patient

Patient Info: Anonymized, Male

He chose annual imaging surveillance of the remaining left breast after deferring chemoprevention.

PubMed CentralRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Dorian's Survivor Story

Patient Info: Dorian de Salvo, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of March 2024, Dorian had a complete response to TCHP chemotherapy, clear surgical margins, and no lymph-node involvement after surgery, with radiation completed and additional care still expected for several months.

The Patient StoryRead more →